Benzinga's Top #PreMarket Gainers

shares gained 13.65% to $8.99 in the pre-market trading session after the company reported that it has been cleared by the FDA to proceed with multiple dose Phase 2b study of ARC-520.

shares climbed 4.69% to $81.05 in pre-market trading. Analysts at Goldman Sachs upgraded Clovis Oncology from Neutral to Buy and raised the price target from $60 to $66.

shares surged 4.47% to $72.25 in pre-market trading as Jana urged spinoff of the chip unit.

gained 2.74% to $31.85 in pre-market trading after the company announced the pricing of 5 million share public offering at $30.96 per share. Baird upgraded Habit Restaurants from Neutral to Outperform.

shares rose 2.73% to $467.00 in pre-market trading. Analysts at UBS upgraded Netflix from Neutral to Buy and raised the price target from $370 to $565.